WeConnectPatients.com · Kidney & Immune Health

Your kidneys are under attack from your own immune system. And you deserve to understand why.

IgA nephropathy isn’t something you caused. It’s an immune system problem that damages your kidneys over time. Here’s what you need to know — explained in plain language.

Primary Kidney Inflammation

The most common primary kidney inflammation worldwide

Significant Kidney Decline

More than 1 in 4 face significant kidney function loss within a decade of diagnosis

Peak Age

Most people are diagnosed in their teens to thirties

Depression/Anxiety

The emotional burden is significant and often unaddressed (based on studies of people with chronic kidney disease)

Your immune system is making antibodies that damage your kidneys. That’s what’s happening.

IgA nephropathy isn’t a lifestyle disease. It’s not something you ate or didn’t eat. Your immune system is producing abnormal antibodies — a type called IgA1 (a subtype of the immune proteins your body normally makes) — that deposit in your kidneys’ filters and trigger inflammation. Over time, that inflammation can scar your kidneys and reduce their ability to do their job.

The first sign for many people is blood in their urine — sometimes visible, sometimes only caught on a lab test. Others find out through routine screening that picks up protein leaking into the urine. Some people feel completely fine when they’re diagnosed. That disconnect between feeling okay and hearing “kidney disease” is one of the hardest parts.

IgAN is the most common form of primary kidney inflammation in the world. It affects people of every background, but it hits hardest in East Asian populations, where incidence is 1.5 to 3 times higher. Peak diagnosis happens between ages 16 and 35, and men are affected about twice as often as women.

Here’s the thing about IgAN that makes it uniquely difficult: the uncertainty. Some people stay stable for decades. Others progress to serious kidney failure within 10 years. About 26% face significant kidney function loss within a decade of diagnosis. You can’t always predict which path you’ll be on, and living with that uncertainty takes a real toll.

What you should know is this: the treatment landscape has changed significantly in the last few years. There are now multiple approved therapies specifically targeting IgAN, with more in development. You have more options today than at any point in history.

What drives IgA nephropathy

IgAN starts with your immune system. But genetics, geography, and other factors shape who gets it and how it progresses.

Your immune system

Your body produces a specific type of antibody called IgA1 with an abnormal sugar coating. These defective antibodies clump together, get trapped in your kidneys’ filtering units, and trigger inflammation. Your kidneys are essentially caught in friendly fire.

Genetics

About 10% of IgAN cases cluster in families. Scientists have identified more than 20 genetic locations linked to the disease. Having a first-degree relative with IgAN significantly raises your risk — but having the genes doesn’t guarantee you’ll develop it.

Geographic and ethnic patterns

IgAN accounts for 40% of primary kidney inflammation in East Asia but only 10% in North America. Part of this is genetic susceptibility. Part of it is screening: countries like Japan screen schoolchildren for urine abnormalities, catching cases earlier. Western healthcare systems mostly don’t.

Infections and triggers

Upper respiratory infections and gut infections can trigger flares. The immune system lining your gut and airways — the same system that fights off colds — appears to play a central role. Some people notice blood in their urine during or right after being sick.

Age and sex

Most people are diagnosed between 16 and 35. Men are affected about twice as often as women. But IgAN can appear at any age and in anyone.

Not your fault

This matters: IgAN is not caused by something you did or didn’t do. It’s an immune system malfunction. Understanding that is the first step toward getting the right help.

How IgA nephropathy is diagnosed

Confirming IgAN requires a kidney biopsy. There’s no way around it — but there’s a clear path through it.

Something shows up in your urine

Blood or protein in your urine, often caught during routine testing. Sometimes it’s visible — tea-colored or pink urine, often during a cold or infection. Sometimes it’s microscopic and only found on a lab test.

Blood work and urine tests

Your doctor measures kidney function using a test called eGFR (estimated glomerular filtration rate — a number that shows how well your kidneys filter waste) and how much protein is leaking into the urine (proteinuria). These numbers establish your baseline and help determine urgency. Serum IgA levels may be elevated but aren’t diagnostic on their own.

Kidney biopsy

A small tissue sample confirms the diagnosis. Under a microscope, IgA deposits light up in the kidney’s filtering units. It’s the only way to be certain — though access to kidney biopsy varies by location and healthcare setting. Talk to your care team about what’s available to you and what the procedure involves. The biopsy also provides a severity score called the Oxford Classification — a standardized grading system that helps your care team predict how IgAN may progress in your case.

Risk stratification

Your nephrologist uses biopsy findings, kidney function, proteinuria levels, and blood pressure to estimate your risk. This shapes how aggressively to treat. Higher proteinuria and lower kidney function at diagnosis generally mean higher risk.

The whole picture

A thorough evaluation includes blood pressure, mental health screening, and family history. Depression and anxiety affect a significant number of people with chronic kidney disease, including IgAN. If your doctor doesn’t ask how you’re doing emotionally, bring it up yourself.

Treatment has changed significantly

Five years ago, the only real option was blood pressure medication and hoping for the best. That has changed.

Foundation

Blood Pressure Medications (RAAS Blockade)

ACE inhibitors or ARBs remain first-line for everyone with IgAN. They lower blood pressure, reduce protein leakage, and protect kidney function. For some people, this is enough. But about 40% progress despite optimal blood pressure control alone.

Newer Standard

SGLT2 (Sodium-Glucose Co-Transporter 2) Inhibitors

Originally developed for diabetes, these medications have shown benefit for kidney protection beyond blood sugar control. According to updated 2025 clinical guidelines, SGLT2 inhibitors are now recommended for IgAN patients with proteinuria, regardless of diabetes status — ask your nephrologist whether this applies to your situation. Evidence shows they reduce protein in the urine and may slow kidney function decline.

Disease-Specific

Targeted Therapies

Multiple new therapies now specifically target the immune mechanisms driving IgAN. Some reduce the abnormal antibody production. Others block complement activation (a process that amplifies kidney inflammation) or endothelin signaling (a pathway that contributes to kidney scarring). These represent a genuine shift from managing symptoms to treating the underlying disease.

Emerging Science

What’s Coming Next

Researchers are developing therapies that target different points in the immune cascade — antibody production, immune cell signaling, complement pathways. Several are in late-stage clinical trials with results under ongoing evaluation. Clinical trials are where you can access these options before they’re widely available.

All treatments have potential side effects. Some newer therapies are expensive. Ask your nephrologist about patient assistance programs.

“Finding out there were treatments that actually target IgAN — not just blood pressure pills — changed everything for me.”

Reflects common patient experiences

If cost is a barrier, ask about patient assistance programs. Some clinical trials provide medications at no cost.

Answers to the questions you actually have

Living with IgA nephropathy raises real, practical questions. Here are honest answers.

Will I need dialysis?

Not necessarily. About 26% of people with IgAN experience significant kidney function decline within 10 years, but that means the majority don’t. Early diagnosis, modern treatments, and consistent monitoring all improve your odds. The key is staying on top of it.

Can IgA nephropathy be cured?

Not yet. But “incurable” doesn’t mean “untreatable.” Several approved therapies now slow or halt progression. Researchers are working on approaches that could eventually reset the immune system. For now, the goal is protecting your kidney function for as long as possible — and the tools to do that have never been better.

Why is there blood in my urine?

Your kidneys’ filters are inflamed, and blood cells leak through. During infections — especially colds or throat infections — this can get worse, sometimes turning urine visibly pink or tea-colored. It’s alarming, but it’s a known feature of the disease. Tell your nephrologist when it happens.

What is a kidney biopsy really like?

It’s an outpatient procedure. You lie on your stomach, they numb the area, and a needle takes a tiny tissue sample guided by ultrasound. Most people describe it as uncomfortable but manageable. You’ll rest for a few hours afterward. Complications are uncommon. The information it provides is irreplaceable.

Is IgA nephropathy genetic? Should my family get tested?

About 10% of cases run in families. If you have IgAN, first-degree relatives should get a simple urine test. It’s not a guarantee they’ll develop it, but catching early signs matters. Talk to your nephrologist about family screening.

Can I have children with IgA nephropathy?

Yes, but it requires planning. Some IgAN medications are not safe during pregnancy. Anyone with IgAN who is pregnant or considering pregnancy should work with both a nephrologist and an OB-GYN — careful coordination between your care teams makes a real difference. Kidney function and blood pressure need close monitoring. Planning ahead matters.

How do I deal with the uncertainty?

Honestly? It’s one of the hardest parts. Not knowing if your kidneys will stay stable or decline is psychologically exhausting. What helps: regular monitoring so you’re not guessing, a nephrologist you trust, and being honest about how it’s affecting your mental health and daily functioning — including fatigue, difficulty concentrating, or feeling mentally foggy. You’re not being dramatic. This is hard.

Does IgA nephropathy affect mental health?

Yes, it can. Depression and anxiety are common in people with chronic kidney disease, including IgAN, and often go unaddressed. The combination of chronic disease, uncertainty about progression, fatigue, and medication burden is genuinely heavy. If you’re struggling, say so. Mental health support should be part of your care plan, not an afterthought.

Research & Progress

The science has never moved this fast

The science behind IgA nephropathy has advanced significantly over the last five years, yielding multiple approved therapies and an active pipeline. Researchers now understand the specific immune pathways that produce the abnormal antibodies, how they damage kidney filters, and where to intervene. That understanding has already produced multiple approved therapies — and there’s more coming.

What’s in the pipeline: therapies targeting different parts of the immune cascade, from the cells that produce defective antibodies to the complement system that amplifies inflammation. Several are in late-stage clinical trials with results under ongoing evaluation. Combination approaches — using multiple targeted therapies together — are being studied to see if they can do more than any single drug alone.

Clinical trials are how these treatments get tested and eventually approved. Participating gives you access to specialized care teams and emerging therapies while contributing to knowledge that helps everyone with IgAN. There’s no obligation. Your standard care continues regardless. And you can leave a trial at any time.

Your kidneys deserve more than “wait and see.” So do you.

The treatment landscape for IgA nephropathy is changing fast. Whether you were just diagnosed or have been managing this for years, there may be new options worth exploring.

Not sure where to start?

Walking into a nephrology appointment with the right questions changes everything. We put together a quick guide.

This content is for educational purposes only and isn’t a substitute for medical advice. Talk to your healthcare provider before making decisions about your care. Information about clinical trials is for general awareness, not an endorsement of any specific study.

Sources: KDIGO, National Kidney Foundation, IgA Nephropathy Foundation, Lancet, NEJM, CJASN, peer-reviewed literature (2013–2025), ClinicalTrials.gov.

WeConnect is a Takeda initiative connecting people to clinical trial opportunities. Visit WeConnectPatients.com.